Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations
- 1 October 2011
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 82 (8), 915-930
- https://doi.org/10.1016/j.bcp.2011.05.001
Abstract
No abstract availableKeywords
Funding Information
- the National Institutes of Health (R01 GM057481, T32-AG000196)
This publication has 166 references indexed in Scilit:
- Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseasesCellular and Molecular Life Sciences, 2010
- Proteomic Analysis of an α7 Nicotinic Acetylcholine Receptor InteractomeJournal of Proteome Research, 2009
- On the nature of partial agonism in the nicotinic receptor superfamilyNature, 2008
- It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and moodProgress in Neurobiology, 2007
- Synthesis of desformylflustrabromine and its evaluation as an α4β2 and α7 nACh receptor modulatorBioorganic & Medicinal Chemistry Letters, 2007
- The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammationBritish Journal of Pharmacology, 2007
- Nootropic α7 nicotinic receptor allosteric modulator derived from GABA A receptor modulatorsProceedings of the National Academy of Sciences, 2007
- Galanthamine and Non-competitive Inhibitor Binding to ACh-binding Protein: Evidence for a Binding Site on Non-α-subunit Interfaces of Heteromeric Neuronal Nicotinic ReceptorsJournal of Molecular Biology, 2007
- Mechanism of action of benzodiazepines on GABAA receptorsBritish Journal of Pharmacology, 2006
- Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammationNature, 2002